Skip to main content
TipRanks
Go Ultimate75% OFF

BeOne Medicines (ONC) AI Stock Analysis

906 Followers
ONC

BeOne Medicines

(NASDAQ:ONC)

Select Model
Rating:76Outperform
Price Target:$438.00â–²(6.49% Upside)
Action:reiterated
Date:11/06/26

The score is driven primarily by the financial turnaround and strong cash flow profile, reinforced by a very positive earnings call with raised 2026 guidance. Technicals are supportive with price above key moving averages and positive momentum. Valuation is the main offset, with a relatively high P/E and no dividend yield provided.

Positive Factors
Profitable growth and cash generationThe company has converted rapid revenue growth into meaningful profitability and cash generation, with high gross margins and strong free-cash-flow conversion. This improves self-funding capacity for commercialization and pipeline investment while strengthening financial resilience over the next several quarters.
Negative Factors
Historical earnings volatilityThe recent profitability inflection remains exposed to execution risk because the company previously generated sizable losses while expanding. If spending rises faster than product growth or launches underperform, earnings and equity could again face pressure, reducing the durability of the turnaround.

BeOne Medicines (ONC) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%30%ONC+17.75%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$43.95B
Dividend Yield
―
Average Volume (3M)
394.11K
Price to Earnings (P/E)
65.9
Beta (1Y)
0.70
Revenue Growth
33.13%
EPS Growth
1272.97%
Country
US
Employees
12,000
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

BeOne Medicines Business Overview & Revenue Model

Company Description

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule...

How the Company Makes Money

BeOne Medicines makes money primarily by commercializing prescription oncology drugs and recording product revenue from sales to wholesalers, distributors, hospitals, specialty pharmacies, and other healthcare channels (depending on market structure)...

BeOne Medicines Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:8.87%|Next Earnings Date:Mar 31, 2027
Earnings Call SentimentPositive

The call was strongly positive, characterized by 33% product revenue growth, substantially higher operating income and free cash flow, raised 2026 guidance, sustained BRUKINSA momentum, and broad progress across hematology and solid tumor programs. The main challenges were the approximately $50 million order-timing benefit, future revenue pressure from biosimilars and potential VBP inclusion, a statutory Medicare Part D headwind, a PHESGO impairment charge, a more modest pace of future margin expansion, and the delayed tacabrutideg filing. Highlights significantly outweighed lowlights.

Positive Updates

Strong Q3 Revenue Growth and Profitability
Product revenue grew 33% year-over-year to approximately $1.9 billion, while total revenue increased to $1.9 billion from $1.4 billion in the prior year. Income from operations grew 157% to $419 million, net income was $385 million, and GAAP diluted earnings per ADS rose to $3.28 from $1.09.

Negative Updates

BRUKINSA Revenue Benefited from Order Timing
U.S. BRUKINSA sales included an approximately $50 million tailwind from order timing, including an extra shipping day in the quarter.

Company Guidance

For 2026, BeOne Medicines raised and narrowed guidance to total revenue of $6.9 billion-$7 billion, gross margin in the high 80% range, operating expenses of $4.9 billion-$5 billion, GAAP operating income of $1.2 billion-$1.3 billion, and non-GAAP operating income of $1.9 billion-$2 billion; it expects a modest net pricing benefit in the U.S. for BRUKINSA for the balance of the year, while looking ahead to 2027, it expects relatively stable net pricing and a flat to modest headwind from the increase in Medicare Part D manufacturer liability, operating expenses growth to be at least consistent with where we have been over the past several years, operating income to continue to grow meaningfully, and the pace of margin expansion to be modest as compared to 2025 and 2026; the current expectation is that the income tax valuation allowance reversal will occur in the fourth quarter and result in a material tax benefit.

BeOne Medicines Financial Statement Overview

Summary

Strong TTM turnaround: ~$6.61B revenue with very high gross margin (~88%), positive EBIT margin (~15.7%) and net margin (~10.7%). Cash generation is a standout with ~$1.79B operating cash flow and ~$1.36B free cash flow, showing solid cash conversion. Balance sheet leverage is manageable (TTM debt-to-equity ~0.22) with improved ROE (~14.3%), though prior multi-year loss/cash-burn history (2022–2024) remains an execution risk if profitability weakens.

Income Statement

78Positive

Balance Sheet

74Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.61B5.34B3.81B2.46B1.42B1.18B
Gross Profit5.91B4.67B3.22B2.08B1.13B1.01B
EBITDA1.43B616.77M-361.24M-738.16M-1.89B-1.39B
Net Income915.57M286.93M-644.79M-881.71M-2.00B-1.46B
Balance Sheet
Total Assets9.88B8.19B5.92B5.81B6.38B8.54B
Cash, Cash Equivalents and Short-Term Investments5.78B4.55B2.63B3.17B4.53B6.62B
Total Debt1.15B2.00B1.08B930.18M596.67M694.64M
Total Liabilities4.06B3.83B2.59B2.27B2.00B2.40B
Stockholders Equity5.82B4.36B3.33B3.54B4.38B6.13B
Cash Flow
Free Cash Flow1.36B941.74M-669.77M-1.75B-1.97B-1.61B
Operating Cash Flow1.79B1.13B-140.63M-1.16B-1.50B-1.30B
Investing Cash Flow-214.86M-276.15M-548.35M60.00M1.08B640.66M
Financing Cash Flow331.44M1.06B193.45M416.48M-18.97M3.64B

BeOne Medicines Technical Analysis

Technical Analysis SentimentPositive
Last Price411.29

Price Trends

50DMA370.24Positive
100DMA351.91Positive
200DMA328.15Positive

Market Momentum

MACD14.04Negative
RSI63.69Neutral
STOCH84.72Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ONC, the sentiment is Positive. The current price of 411.29 is above the 20-day moving average (MA) of 388.82, above the 50-day MA of 370.24, and above the 200-day MA of 328.15, indicating a bullish trend. The MACD of 14.04 indicates Negative momentum. The RSI at 63.69 is Neutral, neither overbought nor oversold. The STOCH value of 84.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ONC.

BeOne Medicines Risk Analysis

BeOne Medicines disclosed 93 risk factors in its most recent earnings report. BeOne Medicines reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Below is a summary of the material factors that make an investment in our ADSs listed on Nasdaq, our ordinary shares listed on the Stock Exchange of Hong Kong Limited, and our ordinary shares issued to permitted investors in China and listed and traded on the Science and Technology Innovation Board of the Shanghai Stock Exchange in Renminbi ("RMB Shares") speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, are set forth herein and should be carefully considered, together with other information in this Quarterly Report and our other filings with the U.S. Securities and Exchange Commission ("SEC"), before making an investment decision regarding our ADSs, ordinary shares or RMB Shares.Q1, 2026
2.The risk factors denoted with a "*", if any, are newly added or have been materially updated from our Annual Report on Form 10-K for the year ended December 31, 2025 (the "Annual Report").Q1, 2026
3.As we are now a Swiss company, our shareholders have broader rights in certain aspects than they would have under Hong Kong law, Chinese law, U.S. law, or previously applicable Cayman Islands law. While these enhanced rights offer increased shareholder participation, our flexibility to swiftly implement certain initiatives or strategies may be limited, and situations may arise where greater flexibility could otherwise provide meaningful benefits to our shareholders.Q4, 2025

BeOne Medicines Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ONC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
EXELEXEL81Outperform$16.37B19.5945.54%―9.12%40.53%
ONCONC76Outperform$46.53B65.8718.24%―33.13%1272.97%
INCYINCY73Outperform$24.51B57.427.11%―24.88%-65.67%
GMABGMAB63Neutral$31.10B43.7212.26%―19.61%-50.40%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ZLABZLAB49Neutral$3.07B-13.51-31.11%―0.25%8.33%
SMMTSMMT43Neutral$9.45B-10.91-138.81%――13.96%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%ONCEXELINCYSMMTZLABGMABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ONC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ONCBeOne Medicines411.2957.5016.25%
EXELExelixis67.1024.9659.23%
INCYIncyte120.2718.9518.70%
SMMTSummit Therapeutics PLC11.82-4.74-28.62%
ZLABZai Lab Ltd23.472.9714.49%
GMABGenmab (Otc)51.5721.0068.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026